Targovax ASA: First quarter 2020 results
Oslo, Norway, 7 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2020 results. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today (details below). HIGHLIGHTS FOR THE FIRST QUARTER 2020 · Entered into an option agreement with IOVaxis Therapeutics for an TG mutant RAS vaccine license and clinical development agreement in China · Presented encouraging data in the mesothelioma study